Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of BMS-986165 in systemic lupus erythematosus
2018-003471-35Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deucravacitinib in systemic lupus erythematosus (SLE), sponsored by Bristol Myers Squibb. Primary endpoint: Primary safety endpoints. Started Apr 2019; status: active.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2018-003471-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003471-35.